Lantern Pharma to meet FDA on HARMONIC trial changes as LP-300 shows early efficacy signal in EGFR L858R-mutant NSCLC post-TKI setting
Written By: Vennela Reddy, BPharm
Reviewed By: Pharmacally Editorial Team
Lantern Pharma Inc. has scheduled a Type C meeting with the U.S. Food and Drug Administration in mid-May 2026 to discuss proposed amendments to its ongoing Phase 2 HARMONIC™ trial (NCT05456256) evaluating LP-300 in non-small cell lung cancer (NSCLC).
The proposed changes are based on emerging clinical data indicating a consistent progression-free survival (PFS) signal in patients with EGFR Exon 21 L858R-mutant NSCLC who have progressed following tyrosine kinase inhibitor (TKI) therapy, including osimertinib, a population with limited treatment options and poor prognosis.
Preliminary data from the HARMONIC™ trial (cutoff April 13, 2026) show that LP-300 in combination with carboplatin and pemetrexed achieved a median PFS of 8.3 months in 16 L858R-mutant patients, with an objective response rate of 43% and a clinical benefit rate of 86%.
The hazard ratio compared with non-L858R patients was 0.37, and the upper confidence interval for PFS was not reached, suggesting potential durability of response in a subset of patients. Multivariable Cox regression analyses confirmed that the L858R mutation remained an independent predictor of improved PFS after adjusting for race, gender, and TP53 mutation status, although these findings are exploratory and based on a small cohort.
Additional analyses suggest a relationship between treatment duration and outcomes, with patients completing six cycles achieving a median PFS of 8.9 months without increased toxicity.
In a small subset of heavily pretreated patients, median PFS reached 13.5 months, and one patient achieved a durable complete response lasting beyond two years, though such findings require confirmation in larger populations.
The company proposes to refine the trial by focusing enrollment on L858R-mutant patients, transitioning to a single-arm Phase 2 Simon two-stage design, and extending treatment duration from six to eight cycles. These changes aim to align with evolving treatment standards and improve trial efficiency while maintaining a biomarker-driven approach.
LP-300 has shown a favourable tolerability profile, with no new or clinically significant toxicities observed when added to chemotherapy. Reported rates of treatment-related serious adverse events and common toxicities such as rash and paronychia were lower compared with published data from other regimens, although cross-trial comparisons are limited by differences in study design.
EGFR-mutant NSCLC represents a substantial global burden, with the L858R mutation accounting for about 40% of cases and up to 100,000 patients annually. Following progression on frontline therapies such as osimertinib, treatment options remain limited, particularly for never-smokers, a group in which this mutation is more prevalent.
Panna Sharma President and Chief Executive Officer, Lantern Pharma Inc stated that while the data are preliminary, the observed efficacy signal is consistent with the underlying biology and supports a more focused development strategy. The upcoming FDA interaction is intended to obtain regulatory guidance on optimizing the trial design and advancing LP-300 as a potential treatment option for patients with limited alternatives.
LP-300 remains an investigational therapy and has not received regulatory approval, and further data from the ongoing HARMONIC™ trial will be required to validate these findings
Reference
About the Writer
Vennela Reddy, B.Pharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.